Interferon-α as the only adjuvant treatment in high-grade osteosarcoma: Long term results of the Karolinska Hospital series

摘要: This experience of single agent interferon-alpha treatment in high-grade osteosarcoma was based on observed anti-osteosarcoma activity laboratory models and started before introduction aggressive combination chemotherapy. From 1971 to 1990, 89 consecutive patients with non-metastatic received semi-purified, leukocyte as adjuvant treatment. 1984, 70 were given a dose 3 MIU daily for one month followed by times weekly an additional 17 months. For 19 treated from 1985 1990 the increased duration extended 3-5 years. All underwent surgery prior interferon The toxicity mainly constitutional long-term virtually absent. With median follow-up 12 years 10-year metastases-free sarcoma specific survival rates 39% 43%, respectively. Only seven survivors after relapse work suggests osteosarcoma. efficacy standard therapy should be explored randomized trials.